
Can-Fite BioPharma Ltd. CANF
$ 1.44
-1.37%
Can-Fite BioPharma Ltd. ROCE Ratio | CANF
Annual ROCE Ratio Can-Fite BioPharma Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -146.69 | -115.03 | -102.84 | -148.89 | -73.29 | -171.3 | -244.89 | -112.02 | 82.74 | 91.65 | 32.02 | 281.75 | -200.03 | 870.47 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 870.47 | -244.89 | 3.12 |
Quarterly ROCE Ratio Can-Fite BioPharma Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -453.22 | -409.37 | -373.0 | -104.04 | -102.84 | -51.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -51.1 | -453.22 | -248.93 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cassava Sciences
SAVA
|
-128.0 | - | - | $ 110 M | ||
|
Selecta Biosciences
SELB
|
-50.95 | - | -8.69 % | $ 126 M | ||
|
Sangamo Therapeutics
SGMO
|
849.73 | - | - | $ 50.4 M | ||
|
Salarius Pharmaceuticals
SLRX
|
-214.2 | - | - | $ 2.64 M | ||
|
Sensei Biotherapeutics
SNSE
|
-119.5 | - | - | $ 17.5 M | ||
|
Sonnet BioTherapeutics Holdings
SONN
|
-146.87 | - | - | $ 826 K | ||
|
Synthetic Biologics
SYN
|
-85.21 | - | 1.32 % | $ 16.2 M | ||
|
Synlogic
SYBX
|
-33.79 | - | - | $ 7.07 M | ||
|
Virios Therapeutics, LLC
VIRI
|
-32.11 | - | 2710.01 % | $ 72.9 M | ||
|
Vallon Pharmaceuticals
VLON
|
-198.85 | - | -6.47 % | $ 5.76 M | ||
|
Vaxart
VXRT
|
5.01 | - | -25.06 % | $ 46.3 M | ||
|
XOMA Corporation
XOMA
|
5.23 | - | - | $ 485 M | ||
|
Repare Therapeutics
RPTX
|
-61.88 | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
-431.71 | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
-261.49 | - | - | $ 26.8 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-141.18 | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-159.95 | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
-128.38 | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-92.11 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-17.17 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.07 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.84 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-25.89 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-134.09 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-46.52 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-1610.96 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-106.49 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-69.47 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-36.31 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B |